期刊文献+

甲基硒酸对人三阴性乳腺癌细胞化疗增敏作用的机制探讨 被引量:6

Sensitization of chemotherapy for human triple-negative breast cancer cells by methylseleninic acid
在线阅读 下载PDF
导出
摘要 目的:观察甲基硒酸(methylseleninic acid,MSA)对人三阴性乳腺癌细胞的化疗增敏作用及其机制。方法:采用MSA联合紫杉醇、阿霉素与三阴性乳腺癌MDA-MB-231细胞株共培养,分别应用CCK-8实验检测化疗药物单药和联合MSA用药时细胞增殖抑制率,并通过计算合用指数,探讨MSA对化疗药物疗效的影响;用流式细胞术检测细胞周期的分布情况;应用Annexin V-FITC/PI双染法检测细胞凋亡变化。结果:不同浓度化疗药物联合MSA后细胞增殖率较单用化疗药物组均下降,呈明显的量-效关系,提示MSA与化疗药物具协同作用;紫杉醇联合MSA时G2/M期细胞较单药明显增多(P<0.05),阿霉素联合MSA时S期细胞较单药明显增多(P<0.05),提示MSA增强了抗肿瘤药物诱导的肿瘤细胞周期阻滞效应;与单用同一浓度的同一化疗药物相比,10nmol/L紫杉醇联合3.5μmol/L MSA后细胞凋亡率由41.1%上升至59.3%(P<0.05),0.5μmol/L阿霉素联合3.5μmol/L MSA后细胞凋亡率由30.2%上升至51.9%(P<0.01),提示MSA增强了抗肿瘤药物诱导肿瘤细胞凋亡的效应。结论:MSA能增强化疗药物阿霉素和紫杉醇对三阴乳腺癌细胞的抗肿瘤效果,其机制之一可能是增强了抗肿瘤药物诱导的肿瘤细胞凋亡和周期阻滞效应。 AIM : To observe the chemosensitization effect of methylseleninic acid (MSA) on human triplenegative breast cancer (TNBC) cells. METHODS: MDA-MB-231 cell line was co-cultured with MSA plus paclitaxel or doxorubicin. The inhibitory rate of cell proliferation was detected by CCK-8 assay. The combination index was calculated to explore the impact of MSA on the efficacy of chemotherapeutic drugs. The cell cycle was analyzed by flow cytometry. Annexin V-FITC/PI double staining was applied to detect the cell apoptosis. RESULTS : Compared with single usage of chemotherapeutic drugs, the cell proliferation rates were decreased when the chemotherapeutic drugs was combined with MSA, suggesting that there is a synergistic relationship between MSA and chemotherapeutic drugs. Compared with the single-agent groups, the G2/M-phase cells in paclitaxel combined with MSA group increased significantly (P 〈0. 05) ,and the S-phase cells increased significantly in doxorubicin combined with MSA group (P 〈 0. 05). These suggested that MSA enhanced the anticancer effect of the drugs by inducing cell cycle arrest. Compared with single usage of 10 nmol/L paclitaxel, the apoptotic rate increased from 41.1% to 59.3% (P 〈0. 05) as 10 nmol/L paclitaxel combined with 3.5 μmol/L MSA was used. Compared with single usage of 0.5 μmol/L doxorubicin, the apoptotic rate increased from 30.2% to 51.9% (P 〈 0.01 ) as 0.5 μmol/L doxorubicin combined with 3.5 μmol/L MSA was used. These suggested that MSA enhanced antitumor effect of the drugs by inducing tumor cell apeptosis. CONCLUSION: MSA enhances the antitumor effects of chemotherapeutic drugs doxorubicin and paclitaxel on TNBC cells. One of the possible mechanisms is the enhancement of indu-cing tumor cell apoptosis and cell cycle arrest.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2013年第11期1990-1993,共4页 Chinese Journal of Pathophysiology
基金 广东省科技计划(No.2008B030301128)
关键词 甲基硒酸 三阴性乳腺癌 化疗增敏 细胞周期阻滞 细胞凋亡 Methylseleninic acid Triple-negative breast cancer Chemosensitization Cell cycle arrest Apoptosis
  • 相关文献

参考文献10

  • 1邱万寿,郝俊文,李玺,吴珏堃,唐勇.硒代胱氨酸对人三阴性乳腺癌细胞的抑制作用[J].中华实验外科杂志,2012,29(10):1983-1985. 被引量:1
  • 2Chen TF,Zheng WJ,Wong YS. Mitochondria-me-diated apoptosis in human breast carcinoma MCF-7 cells induced by a novel selenadiazole derivative[J].Biomedicine and Pharmacotherapy,2008,(02):77-84.
  • 3Hu H,Li GX,Wang L. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin[J].Clinical Cancer Research,2008,(04):1150-1158.doi:10.1158/1078-0432.CCR-07-4037.
  • 4Cleator S,Heller W,Coombes RC. Triple negative breast cancer:therapeutic options[J].Lancet Oncology,2007,(03):235-244.
  • 5蒋光愉,李红,何伟丽,王宁霞.三阴型乳腺癌FOXA1和BRCA1的表达及其对预后的意义[J].中国病理生理杂志,2012,28(7):1230-1234. 被引量:12
  • 6Rakha EA,Ellis IO. Triple-negative/basal-like breast cancer:review[J].Pathology,2009,(01):40-47.
  • 7Dent R,Trudeau M,Pritchard KI. Triple negative breast cancer:clinical features and patterns of recurrence[J].Clinical Cancer Research,2007,(15):4429-4434.
  • 8Huang H,Jiang Z,Wang T. Single-agent capeci-tabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metasta-tic breast cancer[J].Anti-Cancer Drug Design,2012,(07):718-723.
  • 9Hoefig CS,Renko K,K(o)hrle J. Comparison of different selenocompounds with respect to nutritional value vs.toxicity using liver cells in culture[J].Journal of Nutritional Biochemistry,2011,(10):945-955.
  • 10Chintala S,Tóth K,Cao S. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α[J].Cancer Chemotherapy and Pharmacology,2010,(05):899-911.

二级参考文献19

  • 1杨维良,张东伟.乳腺癌基因治疗的研究现状及展望[J].中华实验外科杂志,2005,22(5):633-635. 被引量:15
  • 2Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion [ J ]. Breast Care, 2011, 6(2) : 136 - 141.
  • 3Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer: correlation with luminal subtype A and survival[J]. Clin Cancer Res, 2007, 13(15) : 4415 - 4421.
  • 4Lai E, Prezioso VR, Smith E, et al. HNF -3A, a hepa- tocyte- enriched transcription factor of novel structure is regulated transcriptionally[J]. Genes Dev, 1990, 4(8) : 1427 - 1436.
  • 5Myatt SS, I.am EW. The emerging roles of forkhead box (Fox) proteins in cancer[ J]. Nat Rev Cancer, 2007, 7 (11i : 847 -859.
  • 6Welcsh PL, King MC King, BRCA1 and BRCA2 and the genetics of breast and ovarian cancer[J] Hum Mol Gen- et, 2001, 10(7) : 705 -713,.
  • 7Miki Y, Swensen J, Shattuck - Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI[J]. Science,1994,266(5182) : 66 -71.
  • 8Vaziri SA, Krumroy LM, Elson P, et al. Breast tumor im- munophenotype of BRCA1 - mutation carriers is influ- enced by age at diagnosis[J]. Clin Cancer Res, 2001,7 (7) : 1937 -1945.
  • 9Miyoshi Y, Murase K, Oh K. Basal- like subtype and BRCA1 dysfunction in breast cancers [ J ]. Int J Clin On- col, 2008, 13(5): 395-400.
  • 10Abd E1 - Behim DM, Ball G, Pinder SE, et al. High - throughput protein expression analysis using tissue mi- croarray technolo~, of a large well - characterised series identifies biologically distinct classes of breast cancer con- firming recent cDNA expression analyses [J].Int J Canc- er, 2005, 116(3) : 340 -350.

共引文献11

同被引文献46

  • 1马时岭,东方,季宇彬,栾志伟.海藻硒多糖抗肿瘤作用机制的研究[J].黑龙江医药,2013,26(4):594-596. 被引量:4
  • 2杨庄青,邹天宁,刘德权,李梅,王茂华,李少林.表柔比星联合紫杉醇治疗三阴性乳腺癌的效果分析[J].中国生化药物杂志,2014,34(6):113-115. 被引量:27
  • 3宋照军,王树宁,潘润淑,李敏,田华.富硒乳酸菌的分离、筛选、驯化及富硒研究[J].中国酿造,2004,23(11):4-6. 被引量:43
  • 4郑建仙.硒的微生物转化及在调味料中的应用[J].中国食品工业,1995(7):24-26. 被引量:11
  • 5徐光碧.硒的化学、生物化学及其在生命科学中的应用[M].武汉:华中理工大学出版社,1994.104-109.
  • 6Wanger P D.Selenium in the treatment of heavy metal poisoning and chemical carcinogenesis[J].Journal of Trace Elements and Electrolytes in Health and Disease,1992,6(4):209-221.
  • 7Demirci A,Pometto A L,Cox D J.Enhanced organically bound Selenium yeast production by fed-batch fermentation[J].Journal of Agricultural and Food Chemistry,1999,47(6):2496-2500.
  • 8Dumout E,Vanhaecke F,Cornelis R.Selenium speciation from food source to metabolites:a critical review[J].Analytical and Bioanalytical Chemistry,2006,385(7):1304-1323.
  • 9Dennert G,Zwahlen M,Brinkman M,et al.Selenium for preventing cancer[J].Sao.Paulo.Med.,2012,130(1):67.
  • 10Renard N E,Tompkins T A.Evaluation of methods for total selenium determination in yeast[J].Biology Trace Element Research,2002,88(2):185-191.

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部